Metrion Biosciences announces closure of funding round

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March.

Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.

The new equity investment round was led by the recently launched o2h Ventures Therapeutics Fund, acting via Reyker Securities plc, and supported by existing shareholders.

The o2h Ventures fund invests in early-stage biotech therapeutic and related AI opportunities in the UK and focuses, in particular, on emerging companies in the growing Cambridge biotech cluster.

We are pleased to welcome both o2h Ventures Therapeutics Fund as a new shareholder and Sunil Shah, Managing Partner of o2h Ventures Ltd as an observer on the Metrion board.”

Keith McCullagh, Metrion Chairman​​

We recognize the ion channel biology space as a potentially very valuable source of new drug targets, which is generating a great interest with pharma companies. The Metrion team has deep expertise, and the Company is emerging as a global leader in ion channel drug discovery.”

Sunil Shah, Managing Partner, o2h Ventures


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2019, June 19). Metrion Biosciences announces closure of funding round. News-Medical. Retrieved on June 23, 2024 from

  • MLA

    Metrion Biosciences Limited. "Metrion Biosciences announces closure of funding round". News-Medical. 23 June 2024. <>.

  • Chicago

    Metrion Biosciences Limited. "Metrion Biosciences announces closure of funding round". News-Medical. (accessed June 23, 2024).

  • Harvard

    Metrion Biosciences Limited. 2019. Metrion Biosciences announces closure of funding round. News-Medical, viewed 23 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities